JAK2 and breast carcinoma: In breast cancer, miR-375 not only inhibits the stemness of breast cancer cells, but also reduces the adriamycin resistance of adriamycin resistant MCF-7Adr cells by impeding the JAK2/STAT3 signaling pathway [11].